Get in touch

Submit

Thank you

Pharmaceutical products can often attract patent protection.  This affords the owner a monopoly in that product; however, the monopoly will only last a fixed period, after which it is open season for competitors.  Choosing a strong, resilient brand name will help foster brand loyalty and encourage customers to continue purchasing your product even when other (potentially cheaper) products have become available.  Obtaining a trade mark registration for your brand name allows you to stop other businesses cashing in on your brand loyalty/success.  It also affords protection against inferior products tainting your hard-earned brand recognition.

 

Pharmaceutical trade marks require regulatory approval.  In the UK, the appropriate body is the Medicines and Healthcare Products Regulatory Agency (MHRA).  The MHRA will reject a proposed pharmaceutical brand name if they believe that: (i) consumers will confuse the chosen name with the name of an existing medicine; (ii) the chosen name is misleading; or (iii) the chosen name is considered unsafe.  Regulatory approval is required before a pharmaceutical product can be sold under the chosen name.

 

The MHRA’s assessment of the trade mark is entirely separate to the assessment undertaken by the UK Intellectual Property Office (UKIPO) if/when a UK trade mark application is filed.  The UKIPO will reject a trade mark application if it considers the mark descriptive or non-distinctive (e.g. “strong medicine” or “cough mixture plus”) – such terms are to be kept free for all to use.  If the UKIPO decides that the brand name meets this threshold it will publish it for opposition purposes – this is where an objection can be brought by the owner of an earlier conflicting right.  It is strongly advisable to conduct a trade mark search prior to selecting a brand name so that you have an idea of the risk profile of the mark and the likelihood of a third party objection being raised. 

 

A trade mark registration is generally valid for 10 years and can be renewed for successive 10 year period, potentially indefinitely.  However, bear in mind that ownership of a trade mark registration does not give you the right to sell a pharmaceutical product under the registered name, regulatory approval is required for that.

 

Recommendations in light of the above:

  • Kick-off the naming process as early as possible
  • Pick distinctive, memorable trade marks, not ones that describe your products (or characteristics)
  • Consider multiple potential names, or at least have some fall-back alternatives in mind
  • Conduct searches of the MHRA and trade mark registers at an early stage
  • Subject to the results of the searches, apply to register your trade marks

 

MoreUK IPO update to trademark specification amendment

07.08.2024

UK IPO update to trademark specification amendment

On July 17th 2024, the UK IPO issued a Tribunal Practice Note (TPN) addressing restrictions to specifications of trademark applications and registrations under Tribunal proceedings.

MorePatents, plausibility and data: one year on from G 2/21

02.04.2024

Patents, plausibility and data: one year on from G 2/21

On 23 March 2023, the European Patent Office (EPO) Enlarged Board of Appeal (EBA) published its decision in case G 2/21, concerning plausibility in patent applications. The decision provided useful guidance on how much data needs to be disclosed in a patent application to overcome objections based on the grounds of lack of inventive step and insufficiency. One year on, we take a look at how the EPO has been applying this standard in the life sciences field.

Get in touch

Submit

Thank you